Biodexa Pharmaceuticals Plc (BDRX) has released an update.
Biodexa Pharmaceuticals Plc, a clinical-stage biotech company, has shifted focus to become a therapeutics company, aiming to develop innovative products for diseases with high unmet needs, such as Type 1 diabetes and rare brain cancers. They have completed recruitment for their MTX110 study in recurrent glioblastoma and have in-licensed tolimidone for Type 1 diabetes, which is Phase II ready. The company plans to advance these clinical-stage assets to proof-of-concept before partnering for further development and commercialization.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
